Fill finish manufacturing involves aseptically filling medicines or biological drugs in any form, such as powder, sterile liquid, and suspension, in ampoules, vials, cartridges, and bottle syringes. Many biopharmaceutical products have several stability problems and are fragile in nature during pharmaceutical processing and filling. As a result, these biological drugs are prone to contamination, leading to huge economic losses for pharmaceutical manufacturers. Fill and finish operations provide advanced aseptic solutions to prevent contamination of biopharmaceutical products. Fill-finish manufacturing is an essential condition to guarantee efficacy and safety because it maintains the sterility of components, equipment, and production area. The fill-finish manufacturing includes the manipulation, moving, and packaging of liquid and solid dosage forms.
The global fill-finish manufacturing market size was valued at USD 6.80 billion in 2019 and projected to reach USD 13.81 billion by 2027, growing at a CAGR of 10.1% during the forecast period, 2020-2027. The major factors are the rising technological advancements in fill-finish manufacturing processes and the rapidly growing biopharmaceutical industry. Additionally, the rising adoption of prefilled syringes for parenteral dosage forms and the spike in demand for other pharmaceutical products will spur the global fill-finish manufacturing industry in the future periods. Furthermore, the growing public-private funding to support niche healthcare products and the rise in outsourcing fill-finish products are expected to witness remarkable growth of fill-finish manufacturing. Furthermore, the increasing demand for sterile products and rising R&D investment are expected to propel the demand for fill-finish manufacturing over the coming years.
Moreover, the rise in the launch of new drugs and therapeutics, increasing adoption of effective medicine, and raising funds for clinical research positively impact fill-finish manufacturing in the healthcare industry. Furthermore, the increased awareness about contract manufacturing, rise in demand for biologics, and improving healthcare infrastructure are fueling the demand for the fill-finish manufacturing market. Furthermore, the growing applications of fill-finish manufacturing in the manufacturing and deployment of vaccines and the rise in the extensive R&D activities at the industrial and academic level will bolster the growth of the global fill-finish manufacturing market share. Additionally, the increasing geriatric population rate and growing healthcare demands in the developing world are impelling the growth of the fill-finish manufacturing market across the globe.
Parenteral administration is one of the most notable routes chosen to ensure 100% bioavailability of pharmaceutical products and stimulate the immediate immune response. The constant rise in the development and market availability of parenteral drugs has driven the demand for cost-effective and advance drug delivery devices that promise ease of administration. The rising demand for the prefilled syringes is expected to drive the growth of the fill-finish manufacturing market. The benefits of prefilled syringes over traditional delivery systems include improved safety, accurate dosing, easy administration, and reduced contamination risks. Among drug delivery devices, prefilled syringes represent one of the fastest-growing primary packaging formats, which are also designed for dose administration. From the past several years, there has been an apparent increase in the development of parenteral drugs, which has resulted in an approximately triplex rise in the consumption of prefilled syringes. Thus, the rising adoption of prefilled syringes for parenteral administration drives the market. However, the stringent government regulations and high costs associated with isolators or restricted access barrier systems (RABS) are a factor expected to restrain the growth of this market to a certain extent.
Based on the product, the global fill-finish manufacturing market is segregated into consumables and instruments. Furthermore, the consumables segment is divided into prefilled syringes, vials, cartridges, and other consumables such as bottles, ampoules, and IV bags. The instruments segment is further divided into systems and machines. Standalone systems and integrated systems further segment systems. Machines, on the other hand, are further segmented into automated machines and semi-automated & manual machines.
The consumables segment is estimated to the highest growth over the analysis timeframe. It is due to the rising adoption of prefilled syringes, the growing use of disposable packaging for biologics, and wide applications of vials in lyophilization. In addition, the consumables have a high replacement rate as compared to the machine and systems.
The instruments will grow significantly due to the rising fill-finish systems adoption and the rise in the utilization of fill-finish manufacturing technology in biopharmaceutical companies and contract research organizations.
Based on the end-user, the global fill-finish manufacturing market is segmented into pharmaceutical & biopharmaceutical companies, contract manufacturing organizations, and other end users. Furthermore, the other end-user segment includes research & development laboratories and academic research institutions.
The contract manufacturing organizations segment will dominate the global fill-finish manufacturing market by 2027 due to the increasing outsourcing of fill-finish manufacturing processes from pharmaceutical companies to prevent contamination in feed production and maintenance of the aseptic conditions in the manufacturing facility.
The pharmaceuticals and biotechnology companies are accounted for the largest share of the fill-finish manufacturing market in 2019 because of the increasing use of fill-finish technology in the clinical trial setting and the rise in manufacturing of protein-based therapeutics highly sensitive to heat and other environmental factors. In addition, the advantages of fill finished manufactured products, including ensure product integrity and avoids the deterioration of compounds, will drive the market growth.
The global fill-finish manufacturing market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa by geography. However, Europe is estimated to project considerable growth over 2020-2026. Due to advances in technology, leading industry players offering innovative products, and increasing investments by CMOs & key biopharmaceutical players. In addition, the rise in the incidence of chronic diseases and the rising production of biosimilars & biologics due to the patent expiry are driving the growth of the fill-finish manufacturing industry in Europe.
North America will gain a prominent share of the fill-finish manufacturing market by 2027. Due to the increasing adoption rates of fill-finish manufacturing technologies, continually improving healthcare infrastructure in the region, and innovative research for life-saving drugs.
Companies such as Becton Dickson and Company, IMA Industria Macchine Automatiche S.p.A., West Pharmaceutical Services Inc., Bausch+Strobel, Gerresheimer AG, SGD Pharma, SCHOTT AG, NIPRO, Syntegon Technology GmbH, Stevanato Group, OPTIMA packaging group GmbH, Groninger & Co.GmbH, Vanrx Pharmasystems Inc, Maquinaria Industrial Dara SL, Marchesini Group S.p.A., Bausch Advanced Technologies Group, Steriline S.r.l., AST, Reagent Chemical & Research Inc, Romaco Group, Comecer S.p.A., M & O Perrry Industries Inc and Watson-Marlow Fluid Technology Group are the key players in the global fill-finish manufacturing market.